Literature DB >> 12848452

Prenatal screening, epidemiology, diagnosis, and management of preeclampsia.

Deirdre J Lyell1, Geralyn M Lambert-Messerlian, Linda C Giudice.   

Abstract

The cause of preeclampsia remains unknown. The disease manifests itself across a broad clinical spectrum from mild to severe, conferring vastly different morbidities and suggesting possibly different disease processes. Oxidative stress, endothelial dysfunction, maternal-fetal immune incompatibility, and abnormal placental implantation are among the suggested causes. The need for a marker or set of markers that allow for definitive diagnosis and assessment of future risk of preeclampsia is tremendous. Ultrasound techniques and several markers have been identified that are increased among patients with preeclampsia, but no test is highly sensitive. In the future, a combination of markers likely will be used to assess risk and, establish the diagnosis, and test treatment strategies. Such an approach would allow for more refined treatment studies of patients who are at highest risk for preeclampsia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848452     DOI: 10.1016/s0272-2712(03)00027-1

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  3 in total

1.  First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia.

Authors:  A O Odibo; Y Zhong; K R Goetzinger; L Odibo; J L Bick; C R Bower; D M Nelson
Journal:  Placenta       Date:  2011-06-08       Impact factor: 3.481

2.  Preeclampsia screening from the patient's perspective.

Authors:  B Luchian; M Neagu; L Luchian; R Vladareanu
Journal:  J Med Life       Date:  2016 Jul-Sep

3.  Pesticide exposure and hypertensive disorders during pregnancy.

Authors:  Tina M Saldana; Olga Basso; Donna D Baird; Jane A Hoppin; Clarice R Weinberg; Aaron Blair; Michael C R Alavanja; Dale P Sandler
Journal:  Environ Health Perspect       Date:  2009-06-04       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.